The company is mainly engaged in Chinese and Western patent medicines,
biological products and plastic building materials, etc.
It is a key high-tech enterprise of the Torch Program recognized by the Ministry of Science and Technology.
The company and its major shareholder Dongbao Group have successively developed and launched a large number of state-level new drugs and
leading products such as "Zhennaoning", Dongbao Gantai Tablets, and Naoxuekang Tablets.
The second-phase expansion project of Dongbao genetically recombinant human insulin,
a key national support project for the revitalization of the old industrial base in Northeast China,
with a total investment of 350 million yuan, is intensively introducing and installing advanced foreign equipment.
The company has become one of the largest human insulin production bases in China.